- Home
- HEQ vs AGEN Comparison
HEQ vs AGEN Comparison
Compare HEQ & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HEQ | AGEN |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.9M | 126.2M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | HEQ | AGEN |
|---|---|---|
| Price | $10.78 | $3.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 43.1K | ★ 595.3K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 9.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $106,829,000.00 |
| Revenue This Year | N/A | $67.15 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.08 | $1.38 |
| 52 Week High | $11.84 | $7.34 |
Technical Indicators
Market Signals| Indicator | HEQ | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 30.93 |
| Support Level | $10.70 | $3.26 |
| Resistance Level | $10.82 | $4.00 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 25.01 | 30.49 |
Price Performance
Historical ComparisonAbout HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).